Tocilizumab for Systemic Juvenile Idiopathic Arthritis Reply

被引：12

作者：

De Benedetti, Fabrizio ^{[1
]}

机构：

[1] Osped Pediat Bambino Gesu, Rome, Italy

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 13期

关键词：

MACROPHAGE ACTIVATION SYNDROME; INTERLEUKIN-6;

D O I：

10.1056/NEJMc1301017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1256 / 1257

页数：2

相关论文

共 4 条

[1] Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients [J].

Miettunen, Paivi M. ;

Narendran, Aru ;

Jayanthan, Aarthi ;

Behrens, Edward M. ;

Cron, Randy Q. .

RHEUMATOLOGY, 2011, 50 (02) :417-419

[2] Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6 [J].

Shimizu, Masaki ;

Nakagishi, Yasuo ;

Kasai, Kazuko ;

Yamasaki, Yuichi ;

Miyoshi, Mari ;

Takei, Syuji ;

Yachie, Akihiro .

CYTOKINE, 2012, 58 (02) :287-294

[3]

Strippoli R, J RHEUMATOL IN PRESS

[4] Amplification of the response to toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome [J].

Strippoli, Raffaele ;

Carvello, Francesco ;

Scianaro, Roberta ;

De Pasquale, Loredana ;

Vivarelli, Marina ;

Petrini, Stefania ;

Bracci-Laudiero, Luisa ;

De Benedetti, Fabrizio .

ARTHRITIS AND RHEUMATISM, 2012, 64 (05) :1680-1688